Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | LIG1 | P18858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10194862 | 0.84 | MEN1 (0.38) | KDM1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25329786 | 0.82 | ESR2 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13575754 | 0.82 | SLC6A2 (0.35) | KDM1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10292141 | 0.82 | HTR3A (0.49) | KDM1ARCOR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2159199 | 0.82 | HTR3A (0.49) | KDM1ARCOR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17948228 | 0.81 | SLC18A3 (0.48) | KDM1A | |
| SCHEMBL4890404 | 0.81 | HTR2C (0.56) | KDM1ARCOR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15317743 | 0.79 | HTR2C (0.38) | KDM1ARCOR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3649091 | 0.79 | KDM1A (0.39) | KDM1ARCOR1RECQLSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL10604403 | 0.73 | SLC6A9 (0.45) | KDM1ATDP1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471774-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2471774-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2471773-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2471773-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2471773-A1 | Piperidinyl derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471774-A1 | Piperidinyl derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471774-A1 | Piperidinyl derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471773-A1 | Piperidinyl derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20110245226-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-7985861-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-26 | — | — | US | disclosed |
| US-7601844-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601844-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7553841-B2 | Amino cyclobutylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553841-B2 | Amino cyclobutylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-2049486-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20070208056-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208056-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208056-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2007092681-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007092681-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208056-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | KDM1A 2886/4885RCOR1 316/4885RECQL 4328/4885 |
| US-20110245226-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | KDM1A 2886/4885RCOR1 316/4885RECQL 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.